BioLargo, Inc. develops and commercializes sustainable technologies across cleantech, environmental engineering, water treatment and life sciences. Company updates commonly cover its Aqueous Electrostatic Concentrator, a PFAS treatment technology designed to remove and collect per- and polyfluoroalkyl substances from liquid streams, as well as engineering services and project work in water, wastewater, remediation and minerals processing.
BioLargo news also follows subsidiary activity, including Clyra Medical Technologies and its FDA-cleared wound care products based on Copper-Iodine Complex Technology, distribution partnerships for ViaCLYR, investor communications, annual operating results, and commercialization updates across medical, environmental and battery-related business lines.
BioLargo, Inc. (OTCQB:BLGO) filed its 2020 Annual Report with significant highlights. Revenue reached $2.43 million, a 31% increase from 2019, with fourth-quarter revenue of $900,000, up 36% from the previous quarter. The company reduced debt from $4.8 million to $1.7 million and announced the upcoming commercial launch of its PFAS water treatment solution. BioLargo continues to enhance its strategic partnerships and expand its technology offerings, positioning for future growth despite challenges from the COVID-19 pandemic.
BioLargo, Inc. (OTCQB:BLGO) announces a webcast and conference call on March 31, 2021, at 2 PM PST to discuss its 2020 financial results, releasing them after market close on March 30, 2021. The event will include a Q&A session open to the public. Interested participants can access the webcast on the company's Investor Relations page. BioLargo focuses on innovative environmental solutions and has secured over 80 grants to support its initiatives.
BioLargo, Inc. (OTCQB:BLGO) announced that CEO Dennis Calvert will present at the Q1 Virtual Investor Summit on March 25, 2021, at 1:30 PM ET. This event connects small- and mid-cap companies with investors. Calvert's presentation will showcase the company's sustainable technologies and their deployment across the country. BioLargo specializes in solving environmental challenges, holding numerous patents and grants. The summit features approximately 100 companies and aims to foster direct connections between companies and over 300 qualified investors.
BioLargo, Inc. (OTCQB:BLGO) has been invited to present its innovative AOS (Advanced Oxidation System) water treatment technology at Isle Utilities' iTAG event on March 4, 2021. Industry leaders from companies like Coca-Cola and Shell will participate in this event aimed at exploring sustainable water technologies. The AOS technology excels in efficient disinfection and removal of pharmaceutical micropollutants, making it valuable for various water treatment applications. This opportunity coincides with BioLargo's rollout of AOS through commercial trials at a poultry farm in Alberta, Canada.
BioLargo, Inc. (OTCQB:BLGO) announced it has eliminated $650,000 in debt, primarily due in August 2021. Remaining debts are manageable, with expectations for forgiveness on most SBA loans. This move aligns with reducing costly convertible debt and interest expenses. The company reported ongoing commercial milestones, including a new water treatment project expected to generate $500,000 in revenue and a $2 million project backlog. CEO Dennis P. Calvert emphasized their strong cash position and growth potential through innovative partnerships and technologies aimed at environmental challenges.
BioLargo, Inc. (OTCQB:BLGO) announced the acquisition of EcoMist®, a deodorizing and sanitizing technology, by its subsidiary ONM Environmental. This device installs on waste collection vehicles to spray odor control products during collection, aiming to enhance service for solid waste customers. EcoMist® is easy to install and complements ONM's existing CupriDyne Clean product. The acquisition requires a 10% royalty on sales, aligning with ONM's growth strategy in air quality control. EcoMist® is touted as a unique solution for odor and VOC management.
BioLargo, Inc. (OTCQB:BLGO) announced a significant contract awarded to its subsidiary, BioLargo Engineering, Science & Technologies (BLEST), to aid in the reconfiguration of Regenerative Thermal Oxidizer (RTO) systems at a major East Coast chemical manufacturing plant. This project, linked to a global chemical firm producing phenolic resins, is expected to generate over $500,000 in revenue. The contract's scope may extend over 24 months and involves essential engineering work for energy efficiency improvements.
BioLargo's subsidiary, Clyra Medical Technologies, has launched Clyraguard, a personal disinfectant, on Amazon, enhancing consumer access during the pandemic. The product, with proven 99.999% efficacy against pathogens, is now available for purchase nationwide. Through a partnership with Powerplay Retail, Clyraguard aims to reach major retailers, capitalizing on pandemic demand. The product features eco-friendly ingredients and has received FDA clearance, marking a significant step in making hospital-grade disinfectants accessible to consumers.
Clyra Medical Technologies has launched Clyraguard, a personal disinfectant spray designed for masks and face coverings, now available on Amazon. The product claims to provide a 99.999% antimicrobial efficacy against viruses, including SARS-CoV-2, and received FDA 510(k) clearance. In partnership with Powerplay Retail, Clyraguard will reach major retailers across the U.S., enhancing consumer access. Clyraguard is eco-friendly, alcohol-free, and non-toxic, making it safe for everyday use. This innovative product aims to deliver essential protection amid ongoing pandemic concerns.
BioLargo, Inc. (OTCQB:BLGO) announced record revenues of approximately $650,000 for Q3 2020, a 60% increase from the previous quarter, and about $1.6 million for the nine months ended September 30, 2020, reflecting a 20% year-over-year growth. The company is expanding its supply chain for the Clyraguard product launch, aiming for a capacity of 1,000,000 units monthly. Significant progress in projects related to PFAS treatment is underway, along with new contracts expected to generate substantial revenues. BioLargo's financial health shows improvement with $3.55 million of debt converted to equity.